{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:02:44Z","timestamp":1777629764267,"version":"3.51.4"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"am","delay-in-days":316,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS117278"],"award-info":[{"award-number":["U01NS117278"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS117209"],"award-info":[{"award-number":["U01NS117209"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.expneurol.2022.114294","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T02:19:41Z","timestamp":1670293181000},"page":"114294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Isobolographic analysis of adjunct antiseizure activity of the FDA-approved cannabidiol with neurosteroids and benzodiazepines in adult refractory focal onset epilepsy"],"prefix":"10.1016","volume":"360","author":[{"given":"Victoria","family":"Golub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreevidhya","family":"Ramakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doodipala Samba","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.expneurol.2022.114294_bb0005","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/epi.16355","article-title":"Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions","volume":"60","author":"Anderson","year":"2019","journal-title":"Epilepsia."},{"issue":"4","key":"10.1016\/j.expneurol.2022.114294_bb0010","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/0883073809348355","article-title":"Increased risk of death among children with Lennox-Gastaut syndrome and infantile spasms","volume":"25","author":"Autry","year":"2010","journal-title":"J. Child Neurol."},{"issue":"5","key":"10.1016\/j.expneurol.2022.114294_bb0015","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/j.pain.0000000000002463","article-title":"Sex differences in medical cannabis-related adverse effects","volume":"163","author":"Aviram","year":"2021","journal-title":"Pain."},{"key":"10.1016\/j.expneurol.2022.114294_bb0020","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.phrs.2017.02.022","article-title":"The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors","volume":"119","author":"Bakas","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.expneurol.2022.114294_bb0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.expneurol.2022.114294_bb0030","first-page":"1","article-title":"Synergy, additivism and antagonism in immunosuppression. A critical review","volume":"28","author":"Berenbaum","year":"1977","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114294_bb0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00213-013-3276-5","article-title":"Neurosteroid interactions with synaptic and extrasynaptic GABA-A receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability","volume":"230","author":"Carver","year":"2013","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.expneurol.2022.114294_bb0040","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1124\/jpet.115.229302","article-title":"Neurosteroid structure-activity relationships for functional activation of extrasynaptic delta-GABA-A receptors in the hippocampus","volume":"357","author":"Carver","year":"2016","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"10.1016\/j.expneurol.2022.114294_bb0045","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0165-6147(83)90490-X","article-title":"Analysis of combined drug effects: a new look at a very old problem","volume":"4","author":"Chou","year":"1983","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.expneurol.2022.114294_bb0050","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1528-1167.2005.51204.x","article-title":"Gender differences in epilepsy","volume":"46","author":"Christensen","year":"2005","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.expneurol.2022.114294_bb0055","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1124\/pr.119.017392","article-title":"Sex differences in the epilepsies and associated comorbidities: implications for use and development of pharmacotherapies","volume":"72","author":"Christian","year":"2020","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.expneurol.2022.114294_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157700","article-title":"Kavain, the major constituent of the anxiolytic kava extract, potentiates GABAA receptors: functional characteristics and molecular mechanism","volume":"11","author":"Chua","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.expneurol.2022.114294_bb0065","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.117.246660","article-title":"3\u03b2-methyl-neurosteroid analogs are preferential positive allosteric modulators and direct activators of extrasynaptic \u03b4-subunit \u03b3-aminobutyric acid type A receptors in the hippocampus dentate gyrus subfield","volume":"365","author":"Chuang","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2022.114294_bb0070","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1124\/jpet.117.244673","article-title":"Genetic and molecular regulation of extrasynaptic GABA-A receptors in the brain: therapeutic insights for epilepsy","volume":"364","author":"Chuang","year":"2018","journal-title":"J. Pharmacol. Exp. Therap."},{"issue":"3","key":"10.1016\/j.expneurol.2022.114294_bb0075","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1124\/jpet.119.261735","article-title":"Isobolographic analysis of Antiseizure activity of the GABA type A receptor-modulating synthetic neurosteroids Brexanolone and ganaxolone with tiagabine and midazolam","volume":"372","author":"Chuang","year":"2020","journal-title":"J. Pharmacol. Exp. Therap."},{"issue":"6","key":"10.1016\/j.expneurol.2022.114294_bb0080","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.bbadis.2017.02.003","article-title":"Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy","volume":"1863","author":"Clossen","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"key":"10.1016\/j.expneurol.2022.114294_bb0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0014-2999(82)90264-3","article-title":"Effects of cannabidiol on behavioral seizures caused by convulsants drugs or current in mice","volume":"83","author":"Consroe","year":"1982","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114294_bb0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","article-title":"Cannabinoids and the expanded endocannabinoid system in neurological disorders","volume":"16","author":"Cristino","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.expneurol.2022.114294_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.682","article-title":"Diversity of molecular targets and signaling pathways for CBD","volume":"8","author":"De Almeida","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"issue":"10","key":"10.1016\/j.expneurol.2022.114294_bb0100","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S1474-4422(16)30158-2","article-title":"Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol."},{"issue":"21","key":"10.1016\/j.expneurol.2022.114294_bb0105","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.expneurol.2022.114294_bb0110","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114294_bb0115","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/epi.14628","article-title":"Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial","volume":"60","author":"Devinsky","year":"2019","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.expneurol.2022.114294_bib496","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ane.13305","article-title":"Cannabidiol efficacy independent of clobazam: meta-analysis of four randomized controlled trials","volume":"142","author":"Devinsky","year":"2020","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1016\/j.expneurol.2022.114294_bb0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fphar.2017.00131","article-title":"Protective effects of cannabidiol against seizures and neuronal death in a rat model of mesial temporal lobe epilepsy","volume":"8","author":"Do Val-da Silva","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114294_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.121.000994","article-title":"Therapeutic basis of generic substitution of antiseizure medications","volume":"381","author":"Elmer","year":"2022","journal-title":"J. Pharmacol. Exp. Therap."},{"issue":"4","key":"10.1016\/j.expneurol.2022.114294_bb0130","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.expneurol.2022.114294_bb0135","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug\u2013drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114294_bb0140","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-3-030-57369-0_7","article-title":"Cannabidiol therapy for refractory epilepsy and seizure disorders","volume":"1264","author":"Golub","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.expneurol.2022.114294_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113946","article-title":"Contusion brain damage in mice for modelling of post-traumatic epilepsy with contralateral hippocampus sclerosis: comprehensive and longitudinal characterization of spontaneous seizures, neuropathology, and neuropsychiatric comorbidities","volume":"348","author":"Golub","year":"2022","journal-title":"Exp. Neurol."},{"issue":"S1","key":"10.1016\/j.expneurol.2022.114294_bb0150","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1684\/epd.2020.1135","article-title":"The proposed mechanisms of action of CBD in epilepsy","volume":"22","author":"Gray","year":"2020","journal-title":"Epileptic Disord."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114294_bb0155","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/can.2019.0028","article-title":"Anticonvulsive properties of cannabidiol in a model of generalized seizure are transient receptor potential vanilloid 1 dependent","volume":"5","author":"Gray","year":"2020","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.expneurol.2022.114294_bb0160","first-page":"10","article-title":"Cannabinoids and the endocannabinoid system","volume":"1","author":"Grotenhermen","year":"2006","journal-title":"Can. Underwrit."},{"key":"10.1016\/j.expneurol.2022.114294_bb0165","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/bs.apha.2014.10.007","article-title":"Interactions of flavonoids with ionotropic GABA receptors","volume":"72","author":"Hanrahan","year":"2015","journal-title":"Adv. Pharmacol."},{"issue":"3","key":"10.1016\/j.expneurol.2022.114294_bb0170","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/1060028020948056","article-title":"Continuing burden of refractory epilepsy","volume":"55","author":"Janson","year":"2020","journal-title":"Ann. Pharmacother."},{"issue":"5\u20136","key":"10.1016\/j.expneurol.2022.114294_bb0175","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lfs.2011.05.018","article-title":"Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes","volume":"89","author":"Jiang","year":"2011","journal-title":"Life Sci."},{"key":"10.1016\/j.expneurol.2022.114294_bb0180","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.seizure.2012.03.001","article-title":"Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures","volume":"21","author":"Jones","year":"2012","journal-title":"Seizure"},{"issue":"42","key":"10.1016\/j.expneurol.2022.114294_bb0185","doi-asserted-by":"crossref","first-page":"11229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome","volume":"114","author":"Kaplan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.expneurol.2022.114294_bb0190","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s11064-017-2287-8","article-title":"Evaluation of cannabidiol in animal seizure models by the epilepsy therapy screening program (ETSP)","volume":"42","author":"Klein","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.expneurol.2022.114294_bb0195","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1124\/mol.63.2.289","article-title":"Structural requirements for imidazobenzodiazepine binding to GABA(A) receptors","volume":"63","author":"Kucken","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114294_bb0200","first-page":"1","article-title":"Ganaxolone: first approval","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.expneurol.2022.114294_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108156","article-title":"Cannabidiol anticonvulsant effect is mediated by the PI3K\u03b3 pathway","volume":"176","author":"Lima","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2022.114294_bb0210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","article-title":"A simplified method of evaluating dose-effect experiments","volume":"96","author":"Litchfield","year":"1949","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2022.114294_bb0215","first-page":"285","article-title":"The problem of synergism and antagonism of combined drugs","volume":"3","author":"Loewe","year":"1953","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.expneurol.2022.114294_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.04.011","article-title":"The holy grail of epilepsy prevention: preclinical approaches to antiepileptogenic treatments","volume":"167","author":"L\u00f6scher","year":"2020","journal-title":"Neuropharmacol."},{"key":"10.1016\/j.expneurol.2022.114294_bb0225","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.3389\/fphar.2021.730257","article-title":"Single-target versus multi-target drugs versus combinations of drugs with multiple targets: preclinical and clinical evidence for the treatment or prevention of epilepsy","volume":"12","author":"L\u00f6scher","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114294_bb0230","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00210-008-0305-8","article-title":"Interactions of tiagabine with ethosuximide in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for nonparallel dose-response relationship curves","volume":"378","author":"\u0141uszczki","year":"2008","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114294_bb0235","first-page":"40","article-title":"Isobolographic analysis of interaction between oxcarbazepine and valproate in pentylenetetrazole-induced seizures in mice","volume":"2","author":"\u0141uszczki","year":"2008","journal-title":"J. Pre. Clin. Res."},{"issue":"4","key":"10.1016\/j.expneurol.2022.114294_bb0240","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1528-1157.2003.32702.x","article-title":"Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis","volume":"44","author":"Luszczki","year":"2003","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.expneurol.2022.114294_bb0245","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/sj.npp.1300243","article-title":"Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice","volume":"28","author":"\u0141uszczki","year":"2003","journal-title":"Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114294_bb0250","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/jpet.111.179671","article-title":"Selective GABA transporter inhibitors tiagabine and EF1502 exhibit mechanistic differences in their ability to modulate the ataxia and anticonvulsant action of the extrasynaptic GABAA receptor agonist gaboxadol","volume":"338","author":"Madsen","year":"2011","journal-title":"J. Pharmacol. Exp. Therap."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114294_bb0255","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1389450118666170125144557","article-title":"Cytochrome P450 structure, function and clinical significance: a review","volume":"19","author":"Manikandan","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.expneurol.2022.114294_bb0260","doi-asserted-by":"crossref","first-page":"32768","DOI":"10.1016\/S0021-9258(20)30057-0","article-title":"A single amino acid of the human GABAA receptor \u03b32 subunit determines benzodiazepine efficacy","volume":"269","author":"Mihic","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2022.114294_bb0265","series-title":"AES 2018 Annual Meeting Abstract Database","article-title":"A phase 1 investigation into the potential effects of cannabidiol on CYP3A4-mediated drug-drug interactions in healthy volunteers","author":"Morrison","year":"2018"},{"key":"10.1016\/j.expneurol.2022.114294_bb0270","series-title":"Marijuana: A Reference Handbook - David E. Newton. (2nd Edition) ABC-CLIO, Feb 7, 2013","author":"Newton","year":"2013"},{"issue":"2","key":"10.1016\/j.expneurol.2022.114294_bb0275","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/epi.14629","article-title":"Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models","volume":"60","author":"Patra","year":"2019","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.expneurol.2022.114294_bb0280","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1111\/epi.16674","article-title":"Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs","volume":"61","author":"Patsalos","year":"2020","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.expneurol.2022.114294_bb0285","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: \u03949-tetrahydrocannabinol, cannabidiol and \u03949-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Brit. J. Pharmacol."},{"issue":"Pt B","key":"10.1016\/j.expneurol.2022.114294_bb0290","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.nbd.2014.05.011","article-title":"Gender issues in antiepileptic drug treatment","volume":"72","author":"Perucca","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/j.expneurol.2022.114294_bb0295","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0013-4694(72)90177-0","article-title":"Modification of seizure activity by electrical stimulation: II. Motor seizure","volume":"32","author":"Racine","year":"1972","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"10.1016\/j.expneurol.2022.114294_bb0300","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/B978-0-444-53630-3.00008-7","article-title":"Neurosteroids: endogenous role in the human brain and therapeutic potentials","volume":"186","author":"Reddy","year":"2010","journal-title":"Prog. Brain Res."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114294_bb0305","first-page":"2305","article-title":"Clinical pharmacology of current antiepileptic drugs","volume":"7","author":"Reddy","year":"2014","journal-title":"Intl. J. Pharma. Sci. Nanotech."},{"issue":"Pt B","key":"10.1016\/j.expneurol.2022.114294_bb0310","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.nbd.2014.06.010","article-title":"Neurosteroids and their role in sex-specific epilepsies","volume":"72","author":"Reddy","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"95","key":"10.1016\/j.expneurol.2022.114294_bb0315","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/jnr.23853","article-title":"Sex differences in the anticonvulsant neurosteroids","volume":"2017","author":"Reddy","year":"2017","journal-title":"J. Neurosci. Res."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114294_bb0320","first-page":"129","article-title":"The utility of cannabidiol in the treatment of refractory epilepsy","volume":"17","author":"Reddy","year":"2017","journal-title":"Clin. Pharmacol. Therap."},{"issue":"6","key":"10.1016\/j.expneurol.2022.114294_bb0325","first-page":"5165","article-title":"Clinical pharmacology and therapeutics of antiepileptic drugs for epilepsy and seizure disorders","volume":"13","author":"Reddy","year":"2020","journal-title":"Int. J. Pharm. Sci. Nanotechnol."},{"key":"10.1016\/j.expneurol.2022.114294_bb0330","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/B978-0-444-64123-6.00016-3","article-title":"Brain structural and neuroendocrine basis of sex differences in epilepsy","volume":"175","author":"Reddy","year":"2020","journal-title":"Handb. Clin. Neurol."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114294_bb0335","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13028","article-title":"Neurosteroid replacement therapy for catamenial epilepsy, post-partum depression, and neuroendocrine disorders in women","volume":"34","author":"Reddy","year":"2021","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.expneurol.2022.114294_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114237","article-title":"Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies","volume":"359","author":"Reddy","year":"2023","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2022.114294_bb0345","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.tips.2016.04.003","article-title":"Clinical potential of neurosteroids for CNS disorders","volume":"37","author":"Reddy","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114294_bb0350","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1124\/jpet.115.230151","article-title":"The pharmacological basis of cannabis therapy for epilepsy","volume":"357","author":"Reddy","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2022.114294_bb0355","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1124\/jpet.110.169854","article-title":"The testosterone-derived neurosteroid androstanediol is a positive allosteric modulator of GABAA receptors","volume":"334","author":"Reddy","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.expneurol.2022.114294_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(24)39152-9","article-title":"Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy","volume":"294","author":"Reddy","year":"2000","journal-title":"J. Pharmacol. Exp. Therap."},{"issue":"2\u20133","key":"10.1016\/j.expneurol.2022.114294_bb0365","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.eplepsyres.2010.01.009","article-title":"Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model","volume":"89","author":"Reddy","year":"2010","journal-title":"Epilepsy Res."},{"issue":"3","key":"10.1016\/j.expneurol.2022.114294_bb0370","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1124\/jpet.114.222075","article-title":"Antiseizure activity of midazolam in mice lacking \u03b4-subunit extrasynaptic GABA(A) receptors","volume":"353","author":"Reddy","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.expneurol.2022.114294_bb0375","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/epi.14693","article-title":"Extrasynaptic \u03b3-aminobutyric acid type A receptor-mediated sex differences in the antiseizure activity of neurosteroids in status epilepticus and complex partial seizures","volume":"60","author":"Reddy","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114294_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135753","article-title":"Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis","volume":"750","author":"Reddy","year":"2021","journal-title":"Neurosci. Lett."},{"issue":"6","key":"10.1016\/j.expneurol.2022.114294_bb0385","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.447","article-title":"A comprehensive and advanced mouse model of post-traumatic epilepsy with robust spontaneous recurrent seizures","volume":"2","author":"Reddy","year":"2022","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.expneurol.2022.114294_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114240","article-title":"Efficacy of the FDA-approved cannabidiol on the development and persistence of temporal lobe epilepsy and complex focal onset seizures","volume":"359","author":"Reddy","year":"2023","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2022.114294_bb0395","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-0404.2008.01004.x","article-title":"Benzodiazepines in epilepsy: pharmacology and pharmacokinetics","volume":"118","author":"Riss","year":"2008","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.expneurol.2022.114294_bb0400","article-title":"Evaluation of sex differences in the potential of \u03949-tetrahydrocannabinol, cannabidiol, cannabidiolic acid, and oleoyl alanine to reduce nausea-induced conditioned gaping reactions in Sprague-Dawley rats","author":"Rock","year":"2022","journal-title":"Cannabis Cannabinoid Res."},{"issue":"Pt B","key":"10.1016\/j.expneurol.2022.114294_bb0405","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.yebeh.2016.11.006","article-title":"Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection","volume":"70","author":"Rosenberg","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.expneurol.2022.114294_bb0410","series-title":"Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. (1st Edition)","author":"Russo","year":"2013"},{"issue":"3","key":"10.1016\/j.expneurol.2022.114294_bb0415","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11599020-000000000-00000","article-title":"GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam","volume":"26","author":"Sankar","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.expneurol.2022.114294_bb0420","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJMoa1107494","article-title":"Intramuscular versus intravenous therapy for prehospital status epilepticus","volume":"366","author":"Silbergleit","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.expneurol.2022.114294_bb0425","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.3390\/molecules25215186","article-title":"Molecular targets of cannabidiol in experimental models of neurological disease","volume":"25","author":"Silvestro","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.expneurol.2022.114294_bb0430","series-title":"Drug Synergism and Dose-Effect Data Analysis","author":"Tallarida","year":"2000"},{"key":"10.1016\/j.expneurol.2022.114294_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104117","article-title":"An overview of drug combination analysis with isobolograms","volume":"319","author":"Tallarida","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2022.114294_bb0440","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pharmthera.2006.08.002","article-title":"Interactions between drugs and occupied receptors","volume":"113","author":"Tallarida","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.expneurol.2022.114294_bb0445","article-title":"Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: a systematic review and meta-analysis","volume":"359","author":"Talwar","year":"2022","journal-title":"Exp. Neurol."},{"issue":"11","key":"10.1016\/j.expneurol.2022.114294_bb0450","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects","volume":"32","author":"Taylor","year":"2018","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.expneurol.2022.114294_bb0455","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: A placebo-controlled randomized clinical trial","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.expneurol.2022.114294_bb0460","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1007\/s12035-018-0898-y","article-title":"Prospects of cannabidiol for easing status epilepticus-induced epileptogenesis and related comorbidities","volume":"55","author":"Upadhya","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.expneurol.2022.114294_bb0465","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.yebeh.2017.07.014","article-title":"Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels","volume":"75","author":"Vilela","year":"2017","journal-title":"Epilepsy Behav."},{"issue":"4 Suppl 1","key":"10.1016\/j.expneurol.2022.114294_bb0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5698\/1535-7597.18.4s1.1","article-title":"Summary of antiepileptic drugs available in the United States of America: working toward a world without epilepsy","volume":"18","author":"Vossler","year":"2018","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.expneurol.2022.114294_bb0475","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/jpet.103.051920","article-title":"The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy","volume":"307","author":"Wallace","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2022.114294_bb0480","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1109\/TAU.1967.1161901","article-title":"The use of fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms","volume":"15","author":"Welch","year":"1967","journal-title":"IEEE Trans. Audio Electroacoust."},{"key":"10.1016\/j.expneurol.2022.114294_bb0485","series-title":"American Epilepsy Society Meeting","first-page":"1","article-title":"The human metabolite of cannabidiol, 7-hydroxyl cannabidiol, but not 7-carboxy cannabidiol, is anticonvulsant in the maximal electroshock seizure threshold test (MEST) in mouse","volume":"vol. 1","author":"Whalley","year":"2017"},{"key":"10.1016\/j.expneurol.2022.114294_bb0490","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1124\/jpet.113.203653","article-title":"Estrous cycle regulation of extrasynaptic delta-containing GABA-A receptor plasticity and tonic inhibition in the hippocampus subfields","volume":"346","author":"Wu","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.expneurol.2022.114294_bb0495","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1684\/j.1950-6945.2004.tb00064.x","article-title":"Adverse motor effects induced by antiepileptic drugs","volume":"6","author":"Zaccara","year":"2004","journal-title":"Epileptic Dis."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488622003193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488622003193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:38:16Z","timestamp":1777430296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488622003193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":100,"alternative-id":["S0014488622003193"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2022.114294","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isobolographic analysis of adjunct antiseizure activity of the FDA-approved cannabidiol with neurosteroids and benzodiazepines in adult refractory focal onset epilepsy","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2022.114294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114294"}}